Semaglutide Results Timeline
What the standard Semaglutide research protocol looks like phase by phase, over a typical 16–20+ weeks cycle. This is the escalation schedule from our full dosing protocol, presented as a timeline rather than a table.
Quick Facts
Phase-by-Phase Timeline
Weeks 1–4
Target dose: 0.25 mg (250 mcg)
Weeks 5–8
Target dose: 0.50 mg (500 mcg)
Weeks 9–12
Target dose: 1.0 mg (1,000 mcg)
Weeks 13–16
Target dose: 1.7 mg (1,700 mcg)
Weeks 17+
Target dose: 2.4 mg (2,400 mcg)
Reported in Research
- ✓Dose escalation occurs every 4 weeks to manage GI tolerance.
- ✓Escalate dose every 4 weeks only if prior dose is tolerated.
- ✓16–20+ weeks with gradual escalation.
This timeline reflects the structure of the standard Semaglutide research protocol documented on this site — it is not a guarantee of individual outcomes, and timelines vary between research subjects. All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.